Home / Inspections / 1226606

FDA Inspection 1226606 — Frontida BioPharm Inc

Frontida BioPharm Inc — FEI 2523348

The FDA completed an inspection of Frontida BioPharm Inc on December 7, 2023 in Philadelphia, PA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). Product area: Drugs.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
December 7, 2023
Fiscal Year
2024
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Philadelphia, PA (United States)

Facility

Other inspections at this facility

  • 1316756 (NAI Thu Apr 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1279864 (NAI Tue Jul 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1097023 (VAI Fri Jul 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 1007832 (VAI Fri Mar 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time))
  • 936055 (OAI Fri Jul 17 2015 00:00:00 GMT+0000 (Coordinated Universal Time))

Recent compliance actions

FDA data resources